Dostarlimab-gxly receives accelerated approval from the FDA for dMMR endometrial cancer

Share This Post

August 2021: Dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) received accelerated approval from the Food and Drug Administration for adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA-approved test, who have progressed on or after a prior platinum-containing regimen.

In the GARNET Trial (NCT02715284), a multicenter, multicohort, open-label trial in patients with advanced solid tumours, efficacy was assessed depending on cohort (A1). 71 patients with dMMR recurrent or advanced endometrial cancer who progressed on or after a platinum-containing treatment were included in the efficacy population. Patients were given 500 mg of dostarlimab-gxly intravenously every three weeks for four doses, then 1,000 mg intravenously every six weeks.

Overall response rate (ORR) and duration of response (DOR) were the primary efficacy outcomes, as determined by a blinded independent central review (BICR) in accordance with RECIST 1.1. The ORR was confirmed to be 42.3 percent (95 percent CI: 30.6 percent , 54.6 percent ). The response rate was 12.7 percent for complete responses and 29.6 percent for incomplete responses. With 93.3 percent of patients having durations of less than six months, the median DOR was not met (range: 2.6 to 22.4 months, ongoing at last assessment).

In 34 percent of individuals who received dostarlimab-gxly, serious side effects occurred. Sepsis, acute renal injury, urinary tract infection, abdominal discomfort, and pyrexia were among the serious adverse responses experienced by more than 2% of patients. Fatigue/asthenia, nausea, diarrhoea, anaemia, and constipation were the most prevalent side effects (20%). Anemia and elevated transaminases were the most common grade 3 or 4 adverse events (2%). Pneumonitis, colitis, hepatitis, endocrinopathies, and nephritis are all immune-mediated adverse responses that might occur.

You may like to read : Cancer treatment in India

Dostarlimab-gxly 500 mg every 3 weeks is the recommended dose and schedule (doses 1 through 4). Starting three weeks following dosage 4, dosing is increased to 1,000 mg every six weeks until illness progression or intolerable toxicity. Dostarlimab-gxly should be delivered as a 30-minute intravenous infusion.

Reference : https://www.fda.gov/

Check details here.

Take second opinion on endometrial cancer treatment


Send Details

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Limkato Korea’s first CAR T Cell therapy
CAR T-Cell therapy

Limkato: Korea’s first CAR T Cell therapy

South Korea is making significant strides in **CAR T cell therapy**, highlighted by the approval of **Limkato**, the first domestically developed CAR T therapy by **Curocell** in 2023. This milestone reduces reliance on foreign treatments and boosts Korea’s position in the global biotech industry. With strong government support and cutting-edge research, Korea is poised to advance CAR T therapies further, expanding applications and improving accessibility for cancer patients.

TIL therapy for melanoma in China
Melanoma

TIL therapy for melanoma in China

Tumor-Infiltrating Lymphocyte (TIL) therapy represents a promising advancement in the treatment of melanoma, particularly in cases where traditional treatments have failed. In China, the adoption of TIL therapy is gaining momentum, offering new hope to patients battling this aggressive form of skin cancer.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

CancerFax is the most trusted online platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies.

Send your medical reports and get a free analysis.

🌟 Join us in the fight against cancer! 🌟

Привет,

CancerFax — это самая надежная онлайн-платформа, призванная предоставить людям, столкнувшимся с раком на поздних стадиях, доступ к революционным клеточным методам лечения.

Отправьте свои медицинские заключения и получите бесплатный анализ.

🌟 Присоединяйтесь к нам в борьбе с раком! 🌟